Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Intercept Pharmaceuticals (ICPT)

Intercept Pharmaceuticals (ICPT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,629,108
  • Shares Outstanding, K 32,733
  • Annual Sales, $ 179,800 K
  • Annual Income, $ -309,240 K
  • 60-Month Beta 1.44
  • Price/Sales 19.57
  • Price/Cash Flow N/A
  • Price/Book 26.91

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -2.44
  • Number of Estimates 10
  • High Estimate -1.65
  • Low Estimate -2.84
  • Prior Year -2.97
  • Growth Rate Est. (year over year) +17.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
80.25 +43.15%
on 11/18/19
120.57 -4.72%
on 12/06/19
+32.12 (+38.81%)
since 11/08/19
3-Month
56.76 +102.40%
on 10/10/19
120.57 -4.72%
on 12/06/19
+47.33 (+70.07%)
since 09/10/19
52-Week
56.76 +102.40%
on 10/10/19
131.87 -12.88%
on 02/19/19
+8.89 (+8.39%)
since 12/10/18

Most Recent Stories

More News
Intercept to Host NASH Commercial Day for Investors on December 16, 2019 in New York

Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced...

ICPT : 114.88 (+3.62%)
Intercept Pharma Shares Up 58.0% Since SmarTrend's Buy Recommendation (ICPT)

SmarTrend identified an Uptrend for Intercept Pharma (NASDAQ:ICPT) on October 23rd, 2019 at $69.13. In approximately 2 months, Intercept Pharma has returned 57.98% as of today's recent price of $109.22....

ICPT : 114.88 (+3.62%)
Alcoholic Hepatitis Therapeutic Market Global Research and Clinical Survey 2019 to 2025

The Global Research report provides information regarding market size, share, trends, growth, cost structure, global market competition landscape, market drivers, challenges and opportunity, capacity,...

ALKS : 21.57 (-0.78%)
IMRN : 3.95 (-1.74%)
ICPT : 114.88 (+3.62%)
Intercept Announces Publication of Results from the Interim Analysis of the Phase 3 REGENERATE Study of OCA for the Treatment of Fibrosis Due to NASH in The Lancet

Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced...

ICPT : 114.88 (+3.62%)
Intercept (ICPT) Up 48.6% Since Last Earnings Report: Can It Continue?

Intercept (ICPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ICPT : 114.88 (+3.62%)
Intercept (ICPT) Gains 7.5% YTD on Progress in NASH Space

Intercept (ICPT) stock gains as it becomes the forerunner in the NASH drug race.

NVS : 92.80 (+0.29%)
CNAT : 0.39 (+3.87%)
ICPT : 114.88 (+3.62%)
GILD : 67.08 (+0.22%)
Intercept Pharmaceuticals Appoints Jason Campagna as Chief Medical Officer

Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced...

ICPT : 114.88 (+3.62%)
The Zacks Analyst Blog Highlights: Intercept, CymaBay, Amgen, Global Blood Therapeutics and ChemoCentryx

The Zacks Analyst Blog Highlights: Intercept, CymaBay, Amgen, Global Blood Therapeutics and ChemoCentryx

GBT : 75.95 (+1.12%)
ICPT : 114.88 (+3.62%)
AMGN : 233.84 (+0.44%)
CCXI : 31.13 (+5.06%)
CBAY : 1.70 (-2.30%)
NASH Scorecard Year to Date: The Winners and the Losers

NASH sees a highly rewarding market with candidates of blockbuster potential. Let us take a look at the hits and misses in this space so far this year.

AGN : 185.61 (+0.18%)
CNAT : 0.39 (+3.87%)
ICPT : 114.88 (+3.62%)
GLMD : 6.32 (+5.51%)
CBAY : 1.70 (-2.30%)
MDGL : 118.50 (+1.10%)
Biotech Stock Roundup: CBAY Falls, CCXI Gains, Amgen Acquires Otezla & More

Key highlights of the past week include regulatory and pipeline updates.

GBT : 75.95 (+1.12%)
ALXN : 111.20 (-1.14%)
ICPT : 114.88 (+3.62%)
BIIB : 297.20 (+0.56%)
AMGN : 233.84 (+0.44%)
CCXI : 31.13 (+5.06%)
CBAY : 1.70 (-2.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strongest short term outlook on maintaining the current direction.

See More Share

Trade ICPT with:

Business Summary

Intercept Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver disease. The company's lead product candidate, obeticholic acid, or OCA, is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR)....

See More

Key Turning Points

2nd Resistance Point 118.38
1st Resistance Point 116.63
Last Price 114.88
1st Support Level 111.81
2nd Support Level 108.74

See More

52-Week High 131.87
Last Price 114.88
Fibonacci 61.8% 103.18
Fibonacci 50% 94.31
Fibonacci 38.2% 85.45
52-Week Low 56.76

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar